Based on our findings, we propose that in ccRCC, which typically harbors inactivating SETD2 mutations, the PI3Kβ-AKT axis is essential for growth and migration and that when targeted, is inhibitory to cells with SETD2 loss, therefore revealing tantalizing therapeutic applications. This evidence concerns the gene SETD2 and nonpapillary renal cell carcinoma.